Know what you eat The FDA and CDC are investigating severe health reactions from the Diamond Shruumz brand of chocolate bars, cones, and gummies. The “microdosing” products were sold online and in shops that sell CBD or Delta-8 THC. The backstory: Diamond Shruumz markets its products as “the leading form of microdosing” despite not containing psilocybin, psilocin, or Amanita analytes. The company’s proprietary mix of nootropics and functional mushrooms is not FDA-approved, and the third-party Certificates of Analysis on the company’s official website are for batches from early 2023. What happened: Diamond Shruumz’s products have now been linked to symptoms of seizures, abnormal heart rates, hyper/hypotension, and central nervous system depression. As of June 11, there have been 12 cases reported across eight states, with 10 hospitalizations. As the FDA and state poison controls track the illnesses, consumers are warned to avoid Diamond Shruumz products. The big picture: As psilocybin legislation makes uneven progress across the U.S. and Canada, the climate is ripe for companies to use the gray market to sell untested and potentially hazardous “mushroom” products to uninformed and unsuspecting consumers. You can keep up to date with the FDA’s investigation here. Stay safe, shroomers. Click here to keep reading.